Stocks and Investing Stocks and Investing
Wed, February 22, 2023

Leland Gershell Downgraded (BMRN) to Hold on, Feb 22nd, 2023


Published on 2024-10-28 01:48:21 - WOPRAI, Leland Gershell
  Print publication without navigation


Leland Gershell of Oppenheimer, Downgraded "BioMarin Pharmaceutical Inc." (BMRN) to Hold on, Feb 22nd, 2023.

Leland has made no other calls on BMRN in the last 4 months.



There are 9 other peers that have a rating on BMRN. Out of the 9 peers that are also analyzing BMRN, 4 agree with Leland's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • David Lebowitz of "Citigroup" Initiated at Hold and Held Target at $116 on, Tuesday, February 21st, 2023
  • Kostas Biliouris of "BMO Capital" Initiated at Hold and Held Target at $107 on, Monday, January 30th, 2023
  • Whitney Ijem of "Canaccord Genuity" Initiated at Hold and Held Target at $119 on, Wednesday, January 18th, 2023
  • Andreas Argyrides of "Wedbush" Maintained at Hold with Increased Target to $83 on, Wednesday, January 11th, 2023


These are the ratings of the 5 analyists that currently disagree with Leland


  • Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $130 on, Friday, February 3rd, 2023
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $132 on, Tuesday, January 24th, 2023
  • Akash Tewari of "Jefferies" Maintained at Strong Buy with Increased Target to $120 on, Tuesday, November 29th, 2022
  • Tiago Fauth of "Credit Suisse" Maintained at Buy with Decreased Target to $110 on, Thursday, October 27th, 2022
  • Jessica Fye of "JP Morgan" Maintained at Buy with Decreased Target to $112 on, Monday, October 24th, 2022
Contributing Sources